Basel Medical Group Ltd BMGL PHARMA
Company Overview
Basel Medical Group Ltd provides healthcare services in Singapore. The company offers general and subspecialized orthopedic, including trauma and sports medicine services, such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, and minimally invasive orthopedic procedures, as well as neurosurgical treatments. It also provides health screening services, mental health, woman's health, and general practice services. In addition, its services include consultation, medical diagnosis, and medical and surgical treatments. The company was incorporated in 2023 and is headquartered in Singapore.
Recent Developments
- Jun 2025 Revenue of $11.32M (+12.6% YoY); net profit $-10.64M.
- Trailing 12 Months Year-on-year growth — revenue +67.1%, earnings -613.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.0%, profit CAGR -212.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.03% |
| 1 Year: | 67.10% |
Compounded Profit Growth
| 5 Years: | -212.57% |
| 1 Year: | -613.11% |
Stock Price Performance
| 1 Year: | -81.03% |
| 6 Months: | -32.49% |
| 3 Months: | -33.05% |
| 1 Month: | -16.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.30 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -212.6% CAGR over 5 years.
- Trading 81.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BMGL Basel Medical Group Ltd PHARMA | 4.78 | -0.83 | $7.56M | 0.00% | -127.36% | -147.37% | 2.03% | -212.57% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 10.66M | 9.70M | 10.05M | 11.32M |
| Cost of Revenue | 2.18M | 2.34M | 2.25M | 2.55M |
| Gross Profit | 8.48M | 7.36M | 7.80M | 8.77M |
| Operating Expenses | 6.01M | 5.29M | 5.61M | 10.94M |
| Operating Income | 2.47M | 2.07M | 2.20M | -2.18M |
| EBITDA | 3.28M | 2.93M | 3.11M | -9.67M |
| Interest Expense | 320.87K | 238.60K | 176.24K | 203.95K |
| Pretax Income | 2.39M | 2.13M | 2.40M | -11.05M |
| Tax Provision | 408.48K | 348.28K | 331.76K | -417.39K |
| Net Income | 1.98M | 1.78M | 2.07M | -10.64M |
| Diluted EPS | 0.12 | 0.10 | 0.11 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 16.85M | 15.38M | 16.31M | 18.68M |
| Current Assets | 15.67M | 14.77M | 16.17M | 13.29M |
| Cash & Equivalents | 1.56M | 1.22M | 1.95M | 3.04M |
| Inventory | 69.83K | 94.60K | 72.03K | 489.06K |
| Receivables | 2.01M | 1.44M | 1.67M | 2.15M |
| Total Liabilities | 13.14M | 9.89M | 8.75M | 13.24M |
| Current Liabilities | 7.19M | 6.47M | 7.16M | 10.16M |
| Long Term Debt | 5.31M | 3.40M | 1.58M | - |
| Total Debt | 10.15M | 7.21M | 4.29M | 5.08M |
| Total Equity | 3.71M | 5.49M | 7.56M | 5.43M |
| Shares Outstanding | 18.45M | 18.45M | 18.45M | 18.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 2.79M | 2.60M | 2.51M | -3.18M |
| Investing Cash Flow | -88.50K | -6.16K | -7.92K | -8.57M |
| Financing Cash Flow | -12.92M | -2.94M | -1.77M | 12.97M |
| Capital Expenditure | -88.50K | -6.16K | -7.92K | -437.88K |
| Free Cash Flow | 2.70M | 2.59M | 2.50M | -3.62M |
| Net Change in Cash | -10.22M | -346.24K | 733.61K | 1.22M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | 79.6% | 75.9% | 77.6% | 77.5% |
| Operating Margin % | 23.2% | 21.4% | 21.8% | -19.2% |
| Net Margin % | 18.6% | 18.4% | 20.6% | -94.0% |
| ROE % | 53.4% | 32.5% | 27.4% | -195.7% |
| ROCE % | 25.6% | 23.3% | 24.0% | -25.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 0.03% | 495 | $2.28K |
| 2 | Coston, McIsaac & Partners | - | 4 | $18 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BMGL
Why Did BMGL Stock Slump 18% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNazBlTmV4cFIwTEVJRjhsalBDbV8yd25hZ1cwZGhZTTQ0Q1NQblB3UXpKSERsVG50N3FBdkg4allUc0ozcWV0SVctdFRTZy10aFY4R19LdTVkclFwZmx1OTJIdWdoWFYzcDh2UFdNTW5kYzU1MHNSdHNJUWg2b2duQmlhM0h3NllqVXhvU3…
BMGL - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9VWXF6VER2OGJkOGJYX19aR09MT29GU2I2dVlhaFhsbnNmeGJ6NmNHeGFDalZ1LTl4ZzFZN3MxZVJubVFJaVE?oc=5" target="_blank">BMGL</a> <font color="#6f6f6f">Finviz</font>…
Basel Medical Group Named in New York Securities Class Action Filed in July 2026 - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxNNzVjNTBNMzlCTFJCOVVEVGZWNjB6dnNva2FDak1xRk54U0V5SzJ3cjFubXZUdC12MGFLd21OUS1qTnc5bFh4N2xBOXExSG9BMGRCVVg0NDRHMTZpSWQwaVdXT2JwbkRONVNNZm14N2VIZEVobXp4Z2tIT1dVdHBXWGpXclg3eFRtVG9Ubk…
Basel Medical Group Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOWDl3YmFSdFRvOHFFZkc5RFRKTzQwa1FkRlNsSlhEekNraS05cVMxbUZxYTVORkZFQ0pqdUpOenVIRzJDT1lxVWlFRnZsTGxtYVJVTHUzRjRCWG1QX1U1ejFtaF9qODFVaXRPb3ZhYTRZYjltZ0Uxa0dFdHlKUm1kZXF4TFZ4eUd4bFlIan…
The market is filled with gapping stocks in Wednesday's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQUjZSbHpVV2dNWDNxVTk5eVhhWnZScldSWFdnZ1BWSXVNWGx0Q3RqX1lnT2JRMnZTUlRrOXNucWxjRDlsRzFNU21jd3BCWm1fcDd6WTREUFlZN2tZVXpQbkRjS2xIcW1XSzc0eHFpZHpsN285cEptcEFfVEkxUGZxYTE5WXdWOTVOVC1Gen…
Basel Medical Group (BMGL) Retreats Sharply, Approaches Critical Support at $5.00 - Regression Channel - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxONWFHSHR6OWMzcWRIbHVtcWwxaXhiTlpISnJ5R3VwUHZpOHdpdlJIanJ5a0l0MFktcVBBMmhRaHRsZkcwS0VoMGM1dVhvdURNMC1GSjYwNHNldWNtNVV1ZEw0X0R2djlBTHJCejZ4X2xxSHFJSUc1ZjdFQUxyZGpfTG5YU0JvekNDVnNkNj…
BMGL — Frequently Asked Questions
What is the current share price of Basel Medical Group Ltd (BMGL)?
As of 2026-09-19 21:16 PDT, Basel Medical Group Ltd (BMGL) trades at $4.78 on NasdaqCM. Its 52-week range is $4.51 to $25.20.
What is the market capitalisation of BMGL?
Basel Medical Group Ltd (BMGL) has a market capitalisation of $7.56M on NasdaqCM.
What is the P/E ratio of BMGL?
BMGL trades at a trailing price-to-earnings (P/E) ratio of -0.83. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.46.
What is the return on equity (ROE) of BMGL?
BMGL has a return on equity (ROE) of -147.37%. Its return on capital employed (ROCE) is -127.36%.
Is BMGL a good stock to buy?
This page provides a data-driven analysis of Basel Medical Group Ltd (BMGL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.